Avalo Therapeutics (AVTX) Accumulated Depreciation (2014 - 2015)
Avalo Therapeutics (AVTX) reported Accumulated Depreciation of $60835.0 for Q4 2015, up 62.97% on a YoY basis from $37328.0 in Q4 2014, and up 62.97% quarter-over-quarter from $37328.0 in Q4 2014.
Avalo Therapeutics (AVTX) Accumulated Depreciation (2014 - 2015) Analysis & Trends
Avalo Therapeutics has reported Accumulated Depreciation for 2 years, with the latest figure at $60835.0 in Q4 2015.
- For the quarter ending Q4 2015, Accumulated Depreciation rose 62.97% year-over-year to $60835.0; the trailing twelve-month figure through Dec 2015 stood at $60835.0 (up 62.97% YoY), and the FY2015 full-year result was $60835.0, up 62.97% from the prior year.
- Accumulated Depreciation for Q4 2015 stood at $60835.0, up from $37328.0 in the prior quarter.
- The five-year high for Accumulated Depreciation was $60835.0 in Q4 2015, with the low at $37328.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 60,835.00 |
| Dec 31, 2014 | 37,328.00 |